UK Markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.1800+0.0897 (+4.29%)
At close: 05:56PM BST
Full screen
Previous close2.0903
Open2.1920
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1780 - 2.2200
52-week range2.1780 - 2.2200
Volume495
Avg. volumeN/A
Market cap62.022M
Beta (5Y monthly)2.61
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

    PARIS, May 19, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly-regarded Journal of Neuro-Ophthalmology has published a qualitative study to explore the impact of Leber Hereditary Optic Neuropathy (LHON) on patients and their relatives. The study was fe

  • Business Wire

    GenSight Biologics: Annual General Meeting on May 25, 2022

    PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).

  • Business Wire

    GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

    PARIS, April 29, 2022--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0390.